Summit Partners Public Asset Management LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 101,730 shares of the biopharmaceutical company's stock, valued at approximately $4,520,000. Summit Partners Public Asset Management LLC owned 0.18% of Agios Pharmaceuticals as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Agios Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company's stock worth $162,926,000 after buying an additional 44,583 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in Agios Pharmaceuticals by 1.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company's stock worth $911,000 after acquiring an additional 540 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $946,000. Harbor Capital Advisors Inc. raised its holdings in shares of Agios Pharmaceuticals by 70.0% in the second quarter. Harbor Capital Advisors Inc. now owns 32,770 shares of the biopharmaceutical company's stock valued at $1,413,000 after purchasing an additional 13,494 shares during the last quarter. Finally, Northcape Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter worth $244,000.
Insider Buying and Selling at Agios Pharmaceuticals
In related news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.93% of the company's stock.
Analyst Upgrades and Downgrades
AGIO has been the subject of a number of analyst reports. Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Raymond James restated an "outperform" rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada reiterated an "outperform" rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Finally, StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of "Hold" and an average target price of $52.33.
Read Our Latest Stock Analysis on AGIO
Agios Pharmaceuticals Trading Up 1.2 %
Shares of AGIO traded up $0.73 during mid-day trading on Friday, reaching $59.39. The company's stock had a trading volume of 237,612 shares, compared to its average volume of 694,239. The stock has a market cap of $3.39 billion, a P/E ratio of 5.23 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 1-year low of $20.96 and a 1-year high of $62.58. The business has a 50-day simple moving average of $48.42 and a two-hundred day simple moving average of $45.23.
Agios Pharmaceuticals Company Profile
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Stories
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.